mRNA-1273疫苗诱导的针对SARS-CoV-2变体的抗体的持久性。
Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.
作者信息
Pegu Amarendra, O'Connell Sarah E, Schmidt Stephen D, O'Dell Sijy, Talana Chloe A, Lai Lilin, Albert Jim, Anderson Evan, Bennett Hamilton, Corbett Kizzmekia S, Flach Britta, Jackson Lisa, Leav Brett, Ledgerwood Julie E, Luke Catherine J, Makowski Mat, Nason Martha C, Roberts Paul C, Roederer Mario, Rebolledo Paulina A, Rostad Christina A, Rouphael Nadine G, Shi Wei, Wang Lingshu, Widge Alicia T, Yang Eun Sung, Beigel John H, Graham Barney S, Mascola John R, Suthar Mehul S, McDermott Adrian B, Doria-Rose Nicole A, Arega Jae, Beigel John H, Buchanan Wendy, Elsafy Mohammed, Hoang Binh, Lampley Rebecca, Kolhekar Aparna, Koo Hyung, Luke Catherine, Makhene Mamodikoe, Nayak Seema, Pikaart-Tautges Rhonda, Roberts Paul C, Russell Janie, Sindall Elisa, Albert Jim, Kunwar Pratap, Makowski Mat, Anderson Evan J, Bechnak Amer, Bower Mary, Camacho-Gonzalez Andres F, Collins Matthew, Drobeniuc Ana, Edara Venkata Viswanadh, Edupuganti Srilatha, Floyd Katharine, Gibson Theda, Ackerley Cassie M Grimsley, Johnson Brandi, Kamidani Satoshi, Kao Carol, Kelley Colleen, Lai Lilin, Macenczak Hollie, McCullough Michele Paine, Peters Etza, Phadke Varun K, Rebolledo Paulina A, Rostad Christina A, Rouphael Nadine, Scherer Erin, Sherman Amy, Stephens Kathy, Suthar Mehul S, Teherani Mehgan, Traenkner Jessica, Winston Juton, Yildirim Inci, Barr Lee, Benoit Joyce, Carste Barbara, Choe Joe, Dunstan Maya, Erolin Roxanne, Ffitch Jana, Fields Colin, Jackson Lisa A, Kiniry Erika, Lasicka Susan, Lee Stella, Nguyen Matthew, Pimienta Stephanie, Suyehira Janice, Witte Michael, Bennett Hamilton, Altaras Nedim Emil, Carfi Andrea, Hurley Marjorie, Leav Brett, Pajon Rolando, Sun Wellington, Zaks Tal, Coler Rhea N, Larsen Sasha E, Neuzil Kathleen M, Lindesmith Lisa C, Martinez David R, Munt Jennifer, Mallory Michael, Edwards Caitlin, Baric Ralph S, Berkowitz Nina M, Boritz Eli A, Carlton Kevin, Corbett Kizzmekia S, Costner Pamela, Creanga Adrian, Doria-Rose Nicole A, Douek Daniel C, Flach Britta, Gaudinski Martin, Gordon Ingelise, Graham Barney S, Holman LaSonji, Ledgerwood Julie E, Leung Kwanyee, Lin Bob C, Louder Mark K, Mascola John R, McDermott Adrian B, Morabito Kaitlyn M, Novik Laura, O'Connell Sarah, O'Dell Sijy, Padilla Marcelino, Pegu Amarendra, Schmidt Stephen D, Shi Wei, Swanson Phillip A, Talana Chloe A, Wang Lingshu, Widge Alicia T, Yang Eun Sung, Zhang Yi, Chappell James D, Denison Mark R, Hughes Tia, Lu Xiaotao, Pruijssers Andrea J, Stevens Laura J, Posavad Christine M, Gale Michael, Menachery Vineet, Shi Pei-Yong
机构信息
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Department of Pediatrics, Division of Infectious Disease, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30322, USA.
出版信息
Science. 2021 Sep 17;373(6561):1372-1377. doi: 10.1126/science.abj4176. Epub 2021 Aug 13.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, and angiotensin-converting enzyme 2 (ACE2)–competing antibodies elicited by the messenger RNA (mRNA) vaccine mRNA-1273 over 7 months. Cross-reactive neutralizing responses were rare after a single dose. At the peak of response to the second vaccine dose, all individuals had responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6 months after the primary series of the mRNA-1273 vaccine. Across all assays, B.1.351 had the lowest antibody recognition. These data complement ongoing studies to inform the potential need for additional boost vaccinations.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）突变可能会削弱疫苗诱导的保护性免疫反应，尤其是随着抗体滴度随时间下降。在此，我们评估了SARS-CoV-2变体B.1.1.7（阿尔法）、B.1.351（贝塔）、P.1（伽马）、B.1.429（伊普西龙）、B.1.526（约塔）和B.1.617.2（德尔塔）对信使核糖核酸（mRNA）疫苗mRNA-1273在7个月内引发的结合、中和及血管紧张素转换酶2（ACE2）竞争性抗体的影响。单剂接种后，交叉反应性中和反应很少见。在对第二剂疫苗的反应峰值时，所有个体对所有变体均有反应。在mRNA-1273疫苗的初次接种系列后6个月，大多数受试者中针对变体的结合抗体和功能性抗体持续存在，尽管水平较低。在所有检测中，B.1.351的抗体识别率最低。这些数据为正在进行的研究提供了补充，以了解是否可能需要额外的加强接种。
Zotero 插件